Michael F. Roman - 31 Mar 2026 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Reporting relationship: Director
Issuer ticker: ABT
Reported as of: 31 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Apr 2026, 17:24:18 UTC
Prior SEC filing: 05 Jan 2026
Next SEC filing: 28 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael F. Roman by Jessica H. Paik, Attorney-in-Fact

Key filing fact

Michael F. Roman filed Form 4 for ABBOTT LABORATORIES (ABT) on 02 Apr 2026.

Key facts

This page summarizes Michael F. Roman's Form 4 filing for ABBOTT LABORATORIES (ABT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Apr 2026, 17:24.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001577544 Primary reporting owner

Roman Michael F

Relationship: Director
Address: 100 ABBOTT PARK ROAD, ABBOTT PARK
Signature: /s/ Michael F. Roman by Jessica H. Paik, Attorney-in-Fact
Signature date: 02 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABT transaction Derivative

Stock Equivalent Units

Award

Transaction value
Shares: +367
Change %: +6.2%
Price: $102.67^*
Shares after: 6,283
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 367
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

Footnote F2

Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.